RIVA-LATANOPROST 50 MCG
LATANOPROST : 50 MCG · DIN 02341085 · LABORATOIRE RIVA INC.
Health Canada status: MARKETED
What is RIVA-LATANOPROST?
RIVA-LATANOPROST 50 MCG contains LATANOPROST : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02341085, held by LABORATOIRE RIVA INC., supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 28-May-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02341085 |
|---|---|
| Brand name | RIVA-LATANOPROST |
| Generic / active ingredient | LATANOPROST : 50 MCG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 50 MCG |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01EE01 LATANOPROST |
| AHFS class | 52:40.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-May-2015 |
| Original market date | 2015-05-11 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01EE01 LATANOPROST. 10 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-LATANOPROST | 50 MCG | SOLUTION | ANGITA PHARMA INC. | MARKETED | DIN 02534835 |
| APO-LATANOPROST | 50 MCG | SOLUTION | APOTEX INC | MARKETED | DIN 02296527 |
| JAMP LATANOPROST | 50 MCG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02453355 |
| M-LATANOPROST | 50 MCG | SOLUTION | MANTRA PHARMA INC | MARKETED | DIN 02513285 |
| MED-LATANOPROST | 50 MCG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02426935 |
| MONOPROST | 50 MCG | SOLUTION | LABORATOIRES THEA | MARKETED | DIN 02456230 |
| MYLAN-LATANOPROST | 50 MCG | SOLUTION | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02373041 |
| SANDOZ LATANOPROST | 50 MCG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02367335 |
| XALATAN | 50 MCG | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 02231493 |
| BL LATANOPROST | 50 MCG | SOLUTION | BAUSCH & LOMB INC | CANCELLED PRE MARKET | DIN 02404052 |
Who else supplies LATANOPROST worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LATANOPROST appears in 825 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.